International Journal of Mycobacteriology (Jan 2022)

Tuberculosis treatment-related lichenoid drug eruptions

  • Zeynep Yegin Katran,
  • Ismet Bulut,
  • Aylin Babalık

DOI
https://doi.org/10.4103/ijmy.ijmy_151_22
Journal volume & issue
Vol. 11, no. 4
pp. 469 – 471

Abstract

Read online

Tuberculosis is one of the leading causes of death from infectious diseases in adults worldwide. Drug hypersensitivity in tuberculosis is an important problem affecting the treatment process. Although treatment is started with isoniazid, rifampicin, ethambutol, and pyrazinamide in drug-sensitive tuberculosis patients, it may not always be continued in this way. When hypersensitivity develops under antituberculosis treatment, type 4 hypersensitivity is the most common, and maculopapular drug eruption develops as a subgroup. Lichenoid drug eruption is very rare. We present our case who was diagnosed with pulmonary tuberculosis, who developed lichenoid drug eruption while receiving treatment, and whose treatment was completed by giving the new regimen with successful desensitization.

Keywords